U042 Dysplastic Nevi for Dummies
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
Management of dysplastic nevi remains controversial given the uncertainties surrounding their diagnosis and malignant potential. Recent data suggests that many dysplastic nevi are not necessarily obligate precursors to melanoma but are markers of melanoma risk. This session seeks to use the most up-to-date evidence to guide providers on how to counsel, manage, and follow patients with dysplastic nevi.
LEARNING OBJECTIVES
Examine the controversies and uncertainties surrounding the diagnosis of dysplastic nevi
Outline a management algorithm for dysplastic nevi based on the most recent data in the literature
Discuss new molecular techniques available to better characterize the malignant potential of dysplastic nevi
SCHEDULE
12:30 AM
Introduction to dysplastic nevi
Elizabeth Gates Berry, MD, FAAD
12:35 AM
Histopathology of Dysplastic Nevi
Benjamin Stoff, MD, FAAD
12:50 AM
Controversies Surrounding Dysplastic Nevi and Strategies for Management
Elizabeth Gates Berry, MD, FAAD
1:05 AM
New Technology to Assist with Diagnosis and to Guide Management of Dysplastic Nevi
Ursula Lang, MD, PhD
1:20 AM
Q&A
SPEAKERS
Elizabeth Gates Berry, MD, FAAD
Ursula Lang, MD, PhD
Benjamin Stoff, MD, FAAD
SPEAKER DISCLOSURES
Elizabeth Gates Berry, MD, FAAD
Barco N.V. – Consultant(Fees); Bristol-Myers Squibb – Advisory Board(Fees); Orlucent – Investigator(Grants/Research Funding);
Ursula Lang, MD, PhD
Castle Biosciences – Advisory Board(Honoraria);
Benjamin Stoff, MD, FAAD
No financial relationships exist with ineligible companies.